Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush Sells 17,813 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 17,813 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total value of $320,634.00. Following the completion of the sale, the chief technology officer now directly owns 147,615 shares of the company’s stock, valued at approximately $2,657,070. This trade represents a 10.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Stock Up 5.1 %

Shares of NASDAQ CNTA opened at $17.60 on Wednesday. The firm’s fifty day moving average is $16.56 and its 200 day moving average is $13.46. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on CNTA shares. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. BMO Capital Markets lifted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group increased their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares in the last quarter. Quarry LP boosted its stake in Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at $90,000. Finally, Fred Alger Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter worth $99,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.